Search
Hutchmed: Submits U.S. New Drug Application for Treatment of MET-Driven EGFR-Mutated Lung Cancer
4 day ago /
Read about 0 minute
Author：小编
Hutchmed announced that AstraZeneca has submitted a New Drug Application to the U.S. FDA for the combination therapy of Orpathis and Tagrisso, for the treatment of lung cancer patients with MET-driven progression following EGFR TKI therapy.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
